OCX - Oncocyte Corp Stock Price, Fair Value and News

$2.19-0.02 (-0.90%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OCX Price Action

Last 7 days

-5.6%

Last 30 days

-20.4%

Last 90 days

-34.4%

Trailing 12 Months

-23.2%

OCX RSI Chart

OCX Valuation

Market Cap

36.9M

Price/Earnings (Trailing)

-0.85

Price/Sales (Trailing)

38.33

EV/EBITDA

-0.76

Price/Free Cashflow

-1.81

OCX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OCX Fundamentals

OCX Revenue

Revenue (TTM)

962.0K

Rev. Growth (Yr)

-73.19%

Rev. Growth (Qtr)

10.58%

OCX Earnings

Earnings (TTM)

-43.1M

Earnings Growth (Yr)

-107.94%

Earnings Growth (Qtr)

-197.86%

OCX Profitability

Operating Margin

23.49%

EBT Margin

-4688.46%

Return on Equity

-444.28%

Return on Assets

-61.44%

Free Cashflow Yield

-55.19%

OCX Investor Care

Shares Dilution (1Y)

103.80%

Diluted EPS (TTM)

-4.64

OCX Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	1.3M	962.0K	0
2023	6.5M	6.8M	7.1M	7.2M
2022	8.0M	6.2M	5.3M	2.0M
2021	2.3M	4.2M	4.6M	7.7M
2020	0	0	0	1.2M
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	293.0K
2016	0	0	0	0
2015	0	0	0	397.0K
2014	0	0	0	569.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Oncocyte Corp

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

CEO	Mr. Joshua Riggs
WEBSITE	https://oncocyte.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	75

Oncocyte Corp Frequently Asked Questions

What is the ticker symbol for Oncocyte Corp? What does OCX stand for in stocks?

OCX is the stock ticker symbol of Oncocyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncocyte Corp (OCX)?

As of Fri Dec 20 2024, market cap of Oncocyte Corp is 36.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCX stock?

You can check OCX's fair value in chart for subscribers.

Is Oncocyte Corp a good stock to buy?

The fair value guage provides a quick view whether OCX is over valued or under valued. Whether Oncocyte Corp is cheap or expensive depends on the assumptions which impact Oncocyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCX.

What is Oncocyte Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, OCX's PE ratio (Price to Earnings) is -0.85 and Price to Sales (PS) ratio is 38.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCX PE ratio will change depending on the future growth rate expectations of investors.